Trial Profile
Nolpitantium Besylate In patients with mild to moderate Ulcerative Colitis: a double-blind, placebo-controlled Efficacy and safety, 8-week study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Nolpitantium (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms NICE
- Sponsors Sanofi-Synthelabo
- 07 Apr 2022 Status changed from recruiting to completed.
- 20 Dec 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 11 Aug 2011 New trial record